A 45-year old man with 60 pack-year smoking history (P05, Table 2) was diagnosed with EGFR L858R-mutant stage IV lung adenocarcinoma and received a combination of osimertinib and crizotinib after acquiring MET amplification with an absolute CN of 4.98 at disease progression from first-line erlotinib therapy. Here, MET is linked to lung adenocarcinoma.